Skip to Main Content

CHICAGO — The cancer drug Trodelvy reduced the risk of tumors progressing by 34% compared to chemotherapy in patients with the most common form of metastatic breast cancer — an outcome reported Saturday that met the goals of a large clinical trial conducted by its maker, Gilead Sciences.

Despite the positive results, the future of Trodelvy as a new treatment for women with HR-positive, HER2-negative breast cancer remains unclear. Patients in the trial had advanced disease, but the drug only provided a relatively small benefit. And there’s no definitive evidence yet that Trodelvy will help this group of breast cancer patients live longer.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment